Enabling Scalable RNA-Based Delivery for Next-Generation Gene Editing Therapies
- Exploring key CMC and process development considerations for delivering RNAbased gene editing systems across in vivo (e.g. LNP) and ex vivo manufacturing workflows
- Addressing challenges in achieving consistent editing efficiency while maintaining product quality, potency, and safety across different delivery modalities and target tissues
- Discussing how platform-based development strategies can support scalability, tech transfer, and clinical translation of next-generation genetic medicines